Moreover, ACEIs and ARBs act in part by increasing cardiac ACE2 gene expression or inducing cardiac ACE2 activity [7], which raises the question, do these agents increase the risk of SARS-COV2 infection and/or worsen the prognosis of patients with COVID-19 [8–10]. This evidence concerns the gene ACE2 and COVID-19.